Insights and Analysis

Securities Risk Disclosure Lessons for Life Sciences Companies

27 October 2025

lab samples

Bynder Desktop Image for mobile

The threshold for securities disclosure is very different from the “statistically significant” standard used by most scientists and researchers

Read full article here.

This article is published by Corporate Compliance Insights.

Authored by Jennifer Windom, Elizabeth Jungman, and Bolton Smith.

Contacts

Jennifer S. Windom

Partner

location Washington, D.C.

Elizabeth Jungman

Partner

location Washington, D.C.

Associate

location Washington, D.C.

View more

Related topics

Life Sciences and Health Care

Load more

Related countries

United States

Load more

Articles you may be interested in

A decade later, FDA updates its patient preference information guidance for medical devices

03 April 2026

FDA finalizes guidance on weight-loss devices: Five things manufacturers need to know

24 March 2026

FDA issues guidance on responding to Form 483 observations for CGMP drug inspections

11 March 2026

Insights and Analysis

Life Sciences & Health Care Horizons 2026

11 March 2026

Insights and Analysis

Bundling’s other test: When AKS-friendly discounts create antitrust risk

09 March 2026

FTC proposes to settle with Express Scripts: What it means for manufacturers

27 February 2026

FDA issues guidance on “plausible mechanism” approvals, declares single pivotal trials with confirmatory evidence as new default for all drugs & biologics

25 February 2026

U.S. Supreme Court invalidates IEEPA tariffs, reshaping the Administration’s trade toolkit

23 February 2026

Insights and Analysis

FDA Town Hall Sheds New Light on Updated General Wellness Policy

19 February 2026

View more insights and analysis

Digital Client Solutions

Empowering you to lead change through our digital solutions.

Register now to receive personalized content and more!

Register

Register